Lundbeck Canada donates $2.7 million towards depression study

Tuesday, August 30, 2011 10:25 AM

The Canadian subsidiary of neurological disease specialist Lundbeck has donated $2.7 million towards a nationwide study aimed at identifying biomarkers of major depression and bipolar disorder, according to PharmaTimes.

Lundbeck Canada’s donation will fund the Canadian Depression Biomarker Network, a research initiative involving six academic centers across Canada and led by the Toronto-based University Health Network.

The six centers are the University Health Network (comprising Toronto General and Toronto Western hospitals, Princess Margaret Hospitals and the Toronto Rehabilitation Institute), the Ontario Cancer Biomarker Network, McMaster University, Queen’s University, the University of British Columbia and the University of Calgary.

Future treatment of mood disorders lies in personalized medicine, which entails identifying biomarkers and developing targeted therapies, said Lundbeck Canada and its partners. This in turn calls for large-scale studies to define accurately sub-populations.

The biomarker approach combines clinical data (including measures of anxiety, cognition, function/quality of life, life events, personality and symptom severity) with molecular data to provide measures of gene and protein function in the body as well as brain scans that characterize the function of important mood-regulating brain circuits, the partners noted.

The Canadian Depression Biomarker Network will conduct a large-scale, nationwide research project in which detailed clinical, neuro-imaging, genetic and molecular data will be collected from people with depression during a standardized, two-stage course of treatment.

The research team will then identify individuals whose symptoms remitted and those whose symptoms did not. Informatics and mathematical modeling techniques will be used to profile individual patients, make personalized predictions about treatment responses, develop appropriate treatment algorithms and identify new therapeutic targets.   

Around one in eight people in Canada will develop depression during their lifetime, with the total cost to the Canadian economy estimated at $51 billion per year.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs